Evolving Switch Scene Could Drive Nonprescription Reimbursement – Gottlieb
This article was originally published in The Tan Sheet
Executive Summary
Drug sponsors should work with insurers in advance of nonprescription switches to develop reimbursement plans to benefit consumers, particularly when considering a behind-the-counter switch, former FDA Deputy Commissioner Scott Gottlieb advises
You may also be interested in...
OTC Monograph Woes No Surprise To FDA Commissioner Nominee Gottlieb
Gottlieb was asked only one question about OTC drug regulation during his confirmation hearing before the Senate HELP Committee, but it covered a large part of FDA's current concerns about the OTC market.
OTC Monograph Woes No Surprise To FDA Commissioner Nominee Gottlieb
Gottlieb was asked only one question about OTC drug regulation during his confirmation hearing before the Senate HELP Committee, but it covered a large part of FDA's current concerns about the OTC market.
Risk Management Could Bolster FDA Behind-The-Counter Switches – Gottlieb
FDA's authority to require behind-the-counter sale and other restrictions for some nonprescription switches is strengthened by risk-management provisions of "FDA Revitalization" bills pending in Congress, according to former FDA Deputy Commissioner Scott Gottlieb